PD-L1-话题@MedSci

#PD-L1#

309篇内容 | 7262人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1255141, encodeId=64e81255141e1, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=J Clin Oncol：信迪利单抗联合安罗替尼治疗PD-L1阳性晚期宫颈癌, objectType=article, longId=299549, objectId=91b029954956, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91b029954956, replyNumber=0, likeNumber=102, createdTime=2022-02-25, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91b029954956, moduleTitle=J Clin Oncol：信迪利单抗联合安罗替尼治疗PD-L1阳性晚期宫颈癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91b029954956)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255140, encodeId=f56e125514048, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-1单药使用总体疗效为什么那么低? 此处无关PD-L1是否表达, objectType=article, longId=295371, objectId=d9b52953e178, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9b52953e178, replyNumber=0, likeNumber=60, createdTime=2022-02-11, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9b52953e178, moduleTitle=PD-1单药使用总体疗效为什么那么低? 此处无关PD-L1是否表达, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9b52953e178)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255139, encodeId=6c1512551398c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Transl Lung Cancer Res: PD-L1表达水平与III期NSCLC患者使用durvalumab（德瓦鲁单抗）维持治疗疗效的关系, objectType=article, longId=295314, objectId=762829531471, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=762829531471, replyNumber=0, likeNumber=70, createdTime=2022-02-10, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=762829531471, moduleTitle=Transl Lung Cancer Res: PD-L1表达水平与III期NSCLC患者使用durvalumab（德瓦鲁单抗）维持治疗疗效的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=762829531471)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255138, encodeId=ac6212551388d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=J Immunother Cancer：PD-L1抑制剂atezolizumab（阿替利珠单抗）联合贝伐珠单抗治疗PD-L1高表达的非鳞状非小细胞肺癌（NS-NSCLC）患者的疗效和安全性, objectType=article, longId=295174, objectId=ce4f2951e4a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce4f2951e4a6, replyNumber=0, likeNumber=85, createdTime=2022-02-07, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce4f2951e4a6, moduleTitle=J Immunother Cancer：PD-L1抑制剂atezolizumab（阿替利珠单抗）联合贝伐珠单抗治疗PD-L1高表达的非鳞状非小细胞肺癌（NS-NSCLC）患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce4f2951e4a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255137, encodeId=c543125513e89, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Clin Cancer Res：PD-1/PD-L1抑制剂治疗失败后，NSCLC患者是否还可从派姆单抗+化疗治疗中获益？, objectType=article, longId=295140, objectId=2fc82951409c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fc82951409c, replyNumber=0, likeNumber=110, createdTime=2022-02-06, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fc82951409c, moduleTitle=Clin Cancer Res：PD-1/PD-L1抑制剂治疗失败后，NSCLC患者是否还可从派姆单抗+化疗治疗中获益？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fc82951409c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255136, encodeId=41c4125513674, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-L1高表达（90%）的晚期NSCLC免疫+含铂双药化疗效果不好是什么原因？下一步治疗方法是什么？, objectType=article, longId=294782, objectId=5533294e8241, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5533294e8241, replyNumber=0, likeNumber=62, createdTime=2022-01-28, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5533294e8241, moduleTitle=PD-L1高表达（90%）的晚期NSCLC免疫+含铂双药化疗效果不好是什么原因？下一步治疗方法是什么？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5533294e8241)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255135, encodeId=d88f12551350a, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Front Oncol：PD-L1高表达是肝细胞癌患者手术切除后索拉非尼辅助治疗后复发的独立预测因素, objectType=article, longId=294335, objectId=1c8d29433575, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c8d29433575, replyNumber=0, likeNumber=80, createdTime=2022-01-21, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c8d29433575, moduleTitle=Front Oncol：PD-L1高表达是肝细胞癌患者手术切除后索拉非尼辅助治疗后复发的独立预测因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c8d29433575)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255134, encodeId=58e812551347d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=AJH：PD-L1 过表达与 JAK2-V617F 突变负担相关，并与骨髓增殖性肿瘤中的 9p 单亲二体性相关。, objectType=article, longId=293934, objectId=e987293934a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e987293934a7, replyNumber=0, likeNumber=109, createdTime=2022-01-14, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e987293934a7, moduleTitle=AJH：PD-L1 过表达与 JAK2-V617F 突变负担相关，并与骨髓增殖性肿瘤中的 9p 单亲二体性相关。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e987293934a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255133, encodeId=a6a61255133b2, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=J Clin Invest：MEK抑制剂 cobimetinib联合PD-L1抑制剂 atezolizumab可延长胆道癌(BTC)的PFS, objectType=article, longId=293561, objectId=cf2c293561b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf2c293561b4, replyNumber=0, likeNumber=81, createdTime=2022-01-09, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf2c293561b4, moduleTitle=J Clin Invest：MEK抑制剂 cobimetinib联合PD-L1抑制剂 atezolizumab可延长胆道癌(BTC)的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf2c293561b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255132, encodeId=51b0125513256, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=【收藏】PD-1/PD-L1药物(NMPA/FDA)获批适应症, objectType=article, longId=293239, objectId=482e29323925, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=482e29323925, replyNumber=0, likeNumber=99, createdTime=2022-01-03, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=482e29323925, moduleTitle=【收藏】PD-1/PD-L1药物(NMPA/FDA)获批适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=482e29323925)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255131, encodeId=2925125513145, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=一图读懂中国PD-1/PD-L1 | 2021.12, objectType=article, longId=292832, objectId=c8e7292832c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8e7292832c1, replyNumber=0, likeNumber=0, createdTime=2021-12-29, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8e7292832c1, moduleTitle=一图读懂中国PD-1/PD-L1 | 2021.12, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8e7292832c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255130, encodeId=e831125513059, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Chest：支气管超声引导下针吸穿刺(EBUS-TBNA)获得的标本检测PD-L1表达同样可指导PD1抑制剂在晚期NSCLC患者中的应用, objectType=article, longId=292494, objectId=9f45292494ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f45292494ff, replyNumber=0, likeNumber=75, createdTime=2021-12-23, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f45292494ff, moduleTitle=Chest：支气管超声引导下针吸穿刺(EBUS-TBNA)获得的标本检测PD-L1表达同样可指导PD1抑制剂在晚期NSCLC患者中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f45292494ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255129, encodeId=beec1255129fe, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=罗氏PD-L1+TIGIT双靶用于一线NSCLC治疗，效果惊艳，OS死亡风险降低71%, objectType=article, longId=264997, objectId=3fc926499ed5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fc926499ed5, replyNumber=0, likeNumber=96, createdTime=2021-12-14, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fc926499ed5, moduleTitle=罗氏PD-L1+TIGIT双靶用于一线NSCLC治疗，效果惊艳，OS死亡风险降低71%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fc926499ed5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255128, encodeId=85e212551286f, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=J Clin Oncol：PD-L1低表达的晚期胃或食管腺癌(GEAC)患者免疫检查点抑制剂（ICI）的疗效, objectType=article, longId=221539, objectId=ea642215396a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea642215396a, replyNumber=0, likeNumber=79, createdTime=2021-12-06, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea642215396a, moduleTitle=J Clin Oncol：PD-L1低表达的晚期胃或食管腺癌(GEAC)患者免疫检查点抑制剂（ICI）的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea642215396a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255127, encodeId=5104125512ea8, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=J Immunother Cancer：PD-L1抑制剂avelumab联合/不联合西妥昔单抗治疗既往治疗过的晚期肛管鳞状细胞癌(aSCAC)患者的疗效和安全性：CARACAS研究, objectType=article, longId=221205, objectId=3c79221205ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c79221205ea, replyNumber=0, likeNumber=119, createdTime=2021-11-30, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c79221205ea, moduleTitle=J Immunother Cancer：PD-L1抑制剂avelumab联合/不联合西妥昔单抗治疗既往治疗过的晚期肛管鳞状细胞癌(aSCAC)患者的疗效和安全性：CARACAS研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c79221205ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255126, encodeId=ec0d1255126e3, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Cancers (Basel)：使用机器学习模型研究接受PD-1或PD-L1抑制剂患者甲状腺相关不良事件的相关因素, objectType=article, longId=221104, objectId=afbf22110424, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afbf22110424, replyNumber=0, likeNumber=78, createdTime=2021-11-28, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afbf22110424, moduleTitle=Cancers (Basel)：使用机器学习模型研究接受PD-1或PD-L1抑制剂患者甲状腺相关不良事件的相关因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afbf22110424)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255125, encodeId=038e12551255b, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=胃癌组织中IL-6、STT3A和PD-L1的表达及临床意义, objectType=article, longId=221049, objectId=1c9c22104932, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c9c22104932, replyNumber=0, likeNumber=81, createdTime=2021-11-27, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c9c22104932, moduleTitle=胃癌组织中IL-6、STT3A和PD-L1的表达及临床意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c9c22104932)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255124, encodeId=319f1255124c1, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=胃癌中 TGF-β、 PD-L1 表达与肿瘤免疫表型的关系及其临床意义, objectType=article, longId=221048, objectId=fc0c22104810, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc0c22104810, replyNumber=0, likeNumber=73, createdTime=2021-11-27, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc0c22104810, moduleTitle=胃癌中 TGF-β、 PD-L1 表达与肿瘤免疫表型的关系及其临床意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc0c22104810)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255123, encodeId=3fd61255123a2, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=不可切除III期非小细胞肺癌迎来免疫治疗新时代！PD-L1单抗在中国获批！, objectType=article, longId=220988, objectId=1236220988e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1236220988e5, replyNumber=0, likeNumber=75, createdTime=2021-11-26, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1236220988e5, moduleTitle=不可切除III期非小细胞肺癌迎来免疫治疗新时代！PD-L1单抗在中国获批！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1236220988e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255122, encodeId=2a9c12551229f, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Clin Cancer Res：PD-L1抗体单药或联合TIM-3抗体在MSI-H/dMMR晚期肿瘤中的抗肿瘤活性和安全性, objectType=article, longId=220797, objectId=5c23220e97c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c23220e97c1, replyNumber=0, likeNumber=96, createdTime=2021-11-23, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c23220e97c1, moduleTitle=Clin Cancer Res：PD-L1抗体单药或联合TIM-3抗体在MSI-H/dMMR晚期肿瘤中的抗肿瘤活性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c23220e97c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-L1

2020-05-29

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

J Clin Oncol：信迪利单抗联合安罗替尼治疗PD-L1阳性晚期宫颈癌

2022-02-25

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-1单药使用总体疗效为什么那么低? 此处无关PD-L1是否表达

2022-02-11

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Transl Lung Cancer Res: PD-L1表达水平与III期NSCLC患者使用durvalumab（德瓦鲁单抗）维持治疗疗效的关系

2022-02-10

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

J Immunother Cancer：PD-L1抑制剂atezolizumab（阿替利珠单抗）联合贝伐珠单抗治疗PD-L1高表达的非鳞状非小细胞肺癌（NS-NSCLC）患者的疗效和安全性

2022-02-07

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Clin Cancer Res：PD-1/PD-L1抑制剂治疗失败后，NSCLC患者是否还可从派姆单抗+化疗治疗中获益？

2022-02-06

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-L1高表达（90%）的晚期NSCLC免疫+含铂双药化疗效果不好是什么原因？下一步治疗方法是什么？

2022-01-28

zhaojie88 (审核中...)

前往app查看评论内容

#PD-L1#

Front Oncol：PD-L1高表达是肝细胞癌患者手术切除后索拉非尼辅助治疗后复发的独立预测因素

2022-01-21

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

AJH：PD-L1 过表达与 JAK2-V617F 突变负担相关，并与骨髓增殖性肿瘤中的 9p 单亲二体性相关。

2022-01-14

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

J Clin Invest：MEK抑制剂 cobimetinib联合PD-L1抑制剂 atezolizumab可延长胆道癌(BTC)的PFS

2022-01-09

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

【收藏】PD-1/PD-L1药物(NMPA/FDA)获批适应症

2022-01-03

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

一图读懂中国PD-1/PD-L1 | 2021.12

2021-12-29

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Chest：支气管超声引导下针吸穿刺(EBUS-TBNA)获得的标本检测PD-L1表达同样可指导PD1抑制剂在晚期NSCLC患者中的应用

2021-12-23

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

罗氏PD-L1+TIGIT双靶用于一线NSCLC治疗，效果惊艳，OS死亡风险降低71%

2021-12-14

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

J Clin Oncol：PD-L1低表达的晚期胃或食管腺癌(GEAC)患者免疫检查点抑制剂（ICI）的疗效

2021-12-06

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

J Immunother Cancer：PD-L1抑制剂avelumab联合/不联合西妥昔单抗治疗既往治疗过的晚期肛管鳞状细胞癌(aSCAC)患者的疗效和安全性：CARACAS研究

2021-11-30

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Cancers (Basel)：使用机器学习模型研究接受PD-1或PD-L1抑制剂患者甲状腺相关不良事件的相关因素

2021-11-28

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

胃癌组织中IL-6、STT3A和PD-L1的表达及临床意义

2021-11-27

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

胃癌中 TGF-β、 PD-L1 表达与肿瘤免疫表型的关系及其临床意义

2021-11-27

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

不可切除III期非小细胞肺癌迎来免疫治疗新时代！PD-L1单抗在中国获批！

2021-11-26

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Clin Cancer Res：PD-L1抗体单药或联合TIM-3抗体在MSI-H/dMMR晚期肿瘤中的抗肿瘤活性和安全性

2021-11-23

科室
- - 订阅+
  - 更多科室
工具
服务